bluuebunny/crossref_metadata_2025_split huggingface dataset:
CNSC-69. GLIOBLASTOMA-NETWORK CONNECTIVITY IS REGULATED THROUGH ALTERATIONS IN CHLORIDE HOMEOSTASIS AND GABAERGIC SIGNALING
Authors: Krishna Saritha , Gonzales Cesar Nava , Daniel Andy , Lee Kevin , Dada Abraham , Yamada Hunter , Ambati Vardhaan , Viswanath Pavithra , Hervey-Jumper Shawn 
Published: November 2024

Abstract
The specific pathophysiological mechanisms underlying glioma-related epilepsy, which presents an unfavorable clinical course, are still not well explored. To identify the candidate pathways involved in glioblastoma-induced neuronal hyperexcitability, we used high-density electrode arrays in vivo in humans to record local field potentials from cortically projecting gliomas and identified hyperexcitable intratumoral regions with elevated functional connectivity to the brain. Single-cell RNA sequencing (13,730 cells analyzed) of the functionally connected intratumoral regions identified several circuit assembly and GABAergic signaling genes elevated in glioma-intrinsic neurons, including the sodium-potassium-chloride co-transporter 1 (NKCC1), which accumulates chloride in the cells. We hypothesized that the hyperexcitable behavior of glioma-intrinsic neurons in glioblastoma is mediated by elevated NKCC1 and chloride dysregulation and that inhibiting NKCC1 would reinforce the inhibitory action of GABA and rescue the neuronal hyperresponsive phenotype. Single-nucleus (sNuc-seq) sequencing was performed on neuron-glioblastoma co-cultures (54,000 cells analyzed) to determine NKCC1-facilitated GABAergic signaling in glioblastoma-mediated neuronal responses. Mechanistic and functional studies using perforated whole-cell patch-clamp recordings, multielectrode array, calcium, and chloride imaging for validating therapeutic vulnerabilities to NKCC1 silencing by shRNA knockdown and by the FDA-approved drug bumetanide were performed using in vitro and organotypic mouse slice culture models. sNuc-seq revealed an upregulation of neuronal NKCC1 and GABAA receptors when co-cultured with NKCC1-high-expressing glioblastoma cells, indicating the strong association between neuronal NKCC1 and GABAergic signaling. Electrophysiological analysis of glioblastoma-neuron co-cultures demonstrated increased network burst synchrony and a positive shift in the GABA reversal potential (EGABA). This increase was eliminated in the presence of NKCC1 inhibition using bumetanide and shRNA knockdown, which correlated with a significant decrease in intracellular neuronal chloride. Mechanistically, glioma NKCC1 downregulation significantly decreased GAP43-mediated tumor microtube (TMT) formation. Whether this reduced TMT formation also results in decreased chloride release by glioma cells, thereby altering neuronal chloride equilibrium, is currently under investigation. Collectively, these findings aim to identify a new mechanism of glioma-associated epilepsy, which may provide a novel approach to treatment.
STEM-07. UNVEILING THE ROLE OF HYPOXIA AND TAM-SECRETED TGF-Β1 IN PROMOTING GLIOMA STEM CELL MAINTENANCE VIA YAP/TAZ ACTIVATION IN GLIOBLASTOMA PERI-NECROTIC NICHE
Authors: Shih Ling-Kai , Gruchala Tomasz , Li Jiabo , Lam Nicholas , Brat Daniel 
Published: November 2024

Abstract
Glioblastoma (GBM) is a highly malignant brain tumor with rapid growth and poor outcomes. In the tumor microenvironment (TME), necrosis triggers significant reshaping and rapid progression, marked by tumor-associated macrophages (TAMs) and glioma stem cells (GSCs) accumulation in peri-necrotic zones. Analysis of Ivy-GAP and single-cell RNA-Seq data revealed consistent Hippo pathway activation in the hypoxic peri-necrotic zone, despite canonical stem-cell transcription factors such as SOX2, OLIG2, and FOXM1 not being upregulated. We hypothesize that Hippo transcription activation may promote GSC stemness via direct effects of hypoxia and/or TAM-secreted cytokines. Exposing patient-derived GBM neurospheres to 1% hypoxia increased nuclear YAP1 and TAZ expression, along with CYR61, a Hippo pathway readout, compared to normoxia at 48 hours. Single-cell RNA-Seq identified potential hypoxia-regulated genes upstream of YAP/TAZ, including Zyxin, upregulated in 1% hypoxia-treated cultures, possibly facilitating nuclear YAP/TAZ transport. Culturing GBM cells with primary macrophage-conditioned media activated Hippo transcription, with TGF-β1 identified as a hypoxia-specific driver of malignant cell gene expression with single-cell RNA-Seq analysis using NichenetR. Treating GBM cells with TGF-β1 increased CYR61 expression, signifying Hippo transcription activation. Furthermore, we showed that hypoxia and TGF-β1 synergistically maintained GSCs with extreme limiting dilution assays. In the immunocompetent RCAS/tv-a mouse model, Verteporfin, a YAP/TAZ inhibitor, significantly reduced tumor size and prolonged mouse lifespan. TAZ knockdown similarly extended lifespan and reduced tumor growth, with flow cytometry showing a decrease in CD133/CD44 positive GSC populations in knockdown mice. These findings suggest the conclusion that hypoxia and TAM-secreted TGF-β1 directly stimulate YAP/TAZ activation and potentially promote GSC stemness in the GBM peri-necrotic niche.
STEM-11. MULTIDIMENSIONAL PROFILING OF TUMOR CELL HETEROGENEITY REVEALS CELL-LINEAGE SPECIFIC FUNCTIONS IN SUPRATENTORIAL EPENDYMOMAS
Authors: Jeong Daeun , Danielli Sara G , Maaß Kendra , Ghasemi David R , Tetzlaff Svenja K , Reyhan Ekin , de Biagi-Junior Carlos Alberto Oliveira , Cascio Costanza Lo , Neyazi Sina , Nascimento Andrezza , Haase Rebecca , Englinger Bernhard , Jiang Li , Nguyen Cuong M , Baumgartner Alicia-Christina , Castellani Sophia , Rozowsky Jacob S , Hack Olivia A , Shaw McKenzie L , Lotsch-Gojo Daniela , Bruckner Katharina , Pfister Stefan M , Kool Marcel , Nowakowski Tomasz , Gojo Johannes , Baird Lissa , Alexandrescu Sanda , Pajtler Kristian W , Venkataramani Varun , Filbin Mariella G 
Published: November 2024

Abstract
Supratentorial ependymomas (ST-EPN) are aggressive pediatric brain tumors that are categorized into distinct molecular subgroups. However, the developmental origins, tumor microenvironment, and phenotypic characteristics of tumor subpopulations across these subgroups are still poorly understood. In this study, we explored the human developmental signatures, global spatial organization, and the morphological and migratory tumor cell state behaviors in ST-EPN tumors at unprecedented resolution. We profiled 42 ST-EPN patients encompassing ZFTA-RELA (n = 20), ZFTA-Clusters 1 to 4 (n=20), and ST-YAP1 (n=4) subgroups by single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and live-cell imaging. We identified recurrent tumor cell states across tumors, that cover both generic cell processes (including cycling and mesenchymal/hypoxia) and human embryonic and fetal brain developmental signatures. ST-EPN subgroups displayed distinct developmental signatures, mapping to two separate temporally restricted progenitors-neuroepithelial-like and embryonic-like cells. Additionally, tumors showed diverging patterns of neuronal or ependymal differentiation, with ZFTA-Cluster 3 tumors as especially distinct from other subgroups in both developmental origin and differentiation. Furthermore, by utilizing 10X Xenium and novel algorithms we discovered that mesenchymal/hypoxia is critical for driving global tissue architecture to become more organized. Notably, recurrent tumors exhibited higher proportion of mesenchymal/hypoxia cells and greater structure than primary tumors. Lastly, by superimposing molecular and functional assays in both in vivo and in vitro models, we found that cell states exhibit distinct morphological and migratory behaviors, with neuronal-like cells being the most invasive. Neuronal-like cells especially exhibited distinct behavioral patterns reminiscent of neuronal migration during development. Moreover, we demonstrated the crucial role of neuronal microenvironment in promoting plasticity of cells toward this neuronal lineage. Taken together, we present a multidimensional framework for investigating cellular states within ST-EPN tumors, offering novel insights into their developmental origins, patterns of spatial organization, and cellular behavioral characteristics.
STEM-13. NUCLEAR LOCALIZATION OF ALPHA-1-ANTICHYMOTRYPSIN INCREASES IN GLIOBLASTOMA FOLLOWING STANDARD OF CARE TREATMENT
Authors: González Aura Figueroa , Carrano Anna , Norton Emily S , Russo Marissa , Quiñones-Hinojosa Alfredo , Guerrero-Cázares Hugo 
Published: November 2024

Abstract
Glioblastoma (GBM) is the most common malignant primary brain tumor in adults with a median survival of 8-14 months and 5-year survival rate of 6.9%. Its aggressive nature arises mostly from molecular heterogeneity and resistance to standard of care (SOC), including radiation and temozolomide (TMZ). Recurrence is nearly inevitable, driven by highly invasive brain tumor initiating cells (BTICs). Our previous studies revealed that exposing BTICs to cerebrospinal fluid (CSF) from GBM patients increases cell migration and proliferation compared to non-cancer CSF. Transcriptomic analysis identified the upregulation of the SERPINA3 gene, which encodes alpha-1-antichymotrypsin (ACT). Silencing of SERPINA3 reduces BTIC migration and proliferation and abolishes the promigratory response to GBM-derived CSF, highlighting SERPINA3 as a potential therapeutic target. ACT has been reported to bind to DNA, although the implications of this interaction are unknown. We have previously observed higher levels of intranuclear ACT in human GBM compared to non-cancer brain tissues. We hypothesize that the nuclear localization of SERPINA3 in GBM contributes to increased malignancy, opening the possibility of therapeutically targeting its intranuclear transport. Here, we determined the intracellular localization of ACT in BTICs and GBM and compared it to non-cancer tissues. Additionally, we evaluated whether SOC affected intranuclear localization of ACT. Patient-derived BTICs were treated with TMZ, radiation, and a combination of both, to assess changes in ACT expression via Western Blot, PCR, and ICC. A decrease in cell confluency was correlated with a significant decrease (p&lt;0.05) in SERPINA3 mRNA and overall protein expression when BTICs were treated with TMZ alone or in combination. Interestingly, confocal microscopy revealed a significant increase (p&lt;0.05) in its nuclear localization, particularly with TMZ treatment, indicating a change in its intracellular distribution. Overall, nuclear translocation of SERPINA3 increases in response to SOC with potential implications as a treatment resistance mechanism.
STEM-14. INTEGRATED ANALYSIS OF GLIOBLASTOMA PROGENITOR SUBTYPES REVEALS A TUMOR-DERIVED STEM CELL POPULATION WITH NEURAL AND VASCULAR POTENTIAL
Authors: Fazzari Elisa , Azizad Daria , Li Matthew , Yu Kwanha , Ge Weihong , Nano Patricia , Kan Ryan , Soto Jose , Crouch Elizabeth , Raleigh David , Cadet Dimitri , Tse Christopher , Tum Andrew , Bayley Nicholas , Deneen Benjamin , Patel Kunal , Nathanson David , Bhaduri Aparna 
Published: November 2024

Abstract
Glioblastoma (GBM) exhibits a vast heterogeneity in cell types and states. Recent research highlights the reactivation of neurodevelopmental programs in GBM, contributing to this heterogeneity and, ultimately, therapy resistance. To characterize the landscape of progenitor cell types in human primary GBM, we compiled a meta-atlas of single-cell transcriptomes from seven published studies. Using a novel bioinformatic method for gene program analysis, we derived GBM gene expression meta-modules represented across multiple tumors. Our analyses validated previously described GBM gene programs and revealed novel tumor progenitor subtypes. Among these subtypes, we identified a tumor-derived stem cell population exhibiting a mixed vascular identity and transcriptional programs reminiscent of neural stem cells, which we identified as a putative neurovascular progenitor (NVP). To our knowledge, this population has not been previously described in GBM. We validated the existence of NVPs in situ using immunofluorescence from primary patient GBM samples. We then performed an enrichment for NVPs using fluorescence-activated cell sorting direct from patient tumors, followed by single-cell RNA sequencing. Examination of data from traditional model systems, including gliomaspheres and mouse GBM models, confirmed the preservation of NVP identity across systems. In vivo analysis of NVPs in multiple mouse models of GBM elucidate the influence of NVPs on GBM cell type composition, highlighting their role as multipotent progenitors. Finally, we utilized single-cell lineage barcoding to trace the progeny of patient-derived NVP cells in a novel organoid transplantation model, revealing NVP differentiation into vascular-like and neural-like cells. These data indicate that NVP cells play crucial roles in tumor plasticity and may represent a valuable therapeutic target for future exploration.
STEM-15. THE IMPACT OF TUMOR TREATING FIELDS (TTFIELDS) ON CANCER STEM-LIKE CELLS ISOLATED FROM THE SUB-VENTRICULAR ZONE OF GLIOBLASTOMA PATIENTS
Authors: Muñoz Yamhilette Licón , Sidebottom Rachel B , Varela Samantha , Bowers Christian A , Piccirillo Sara G M 
Published: November 2024

Abstract
Treatment of glioblastoma (GBM) is challenging due to its heterogeneous nature, invasive potential, and poor response to standard-of-care treatments. Areas of residual disease represent the source of the recurrent tumor that is fatal for GBM patients. However, targeting the residual disease is not offered as part of the standard of care because these areas are difficult to identify. Our laboratory was the first to identify and characterize residual disease in the sub-ventricular zone (SVZ) of the lateral ventricles of GBM patients. In this study, we are examining the impact of Tumor Treating Fields (TTFields) on treatment-resistant cancer stem-like cells (CSCs) isolated from the SVZ of 12 GBM patients using single-cell transcriptomics and functional phenotyping analysis. These cells are maintained in conditions that preserve the molecular profile of the original patient tumor, thus representing bona fide models to study the impact of TTFields on GBM residual disease. Our results show that: CSCs isolated from the SVZ from different individuals show different sensitivity to TTFields, the anti-proliferative effects of TTFields are maintained at different plating cell densities, and when the frequency of TTFields increase from 50 kHz to 200 kHz, CSCs undergo morphological changes (e.g., fewer spheres and fewer connections between cells). We used 100 μM Temozolomide and ionizing radiation (10 Gy) mimicking the standard of care of GBM patients, and the growth of the treatment-resistant CSCs was inhibited by TTFields (200 kHz). To elucidate how TTFields impact the cellular and molecular characteristics of CSCs in their microenvironment, ongoing work focuses on single-cell transcriptomics and functional phenotyping analysis. These results extend our understanding of the mechanisms of action of TTFields, specifically on how TTFields have the potential to alter the cytokine-mediated cross-talk between CSCs of the SVZ and their microenvironment.
STEM-18. A HIGH THROUGHPUT NEUROSPHERE BASED COLONY FORMATION ASSAY TO VALIDATE DRUG AND RADIATION EFFECTIVENESS IN PATIENT DERIVED XENOLINES
Authors: Kumar Manoj , Anderson Joshua , Alrefai Hasan , Nassour Lauren , Schanel Taylor , Hicks Patricia , Willey Christopher 
Published: November 2024

Abstract
Glioblastoma (GBM) is a primary malignant brain tumor developed from normal astrocytes. GBM patients’ median survival is less than 2 years despite safe surgical resection, fractionated conventional radiation, and temozolomide (TMZ) therapy. Few currently used drugs are successful in GBM although there are many FDA approved blood-brain barrier (BBB) penetrant drugs, for other uses that have not been screened in GBM. We utilized a panel of 734 of these BBB penetrant drugs in different GBM patient derived xenolines (PDX) along with acquired radio-resistant derivatives (-RT) including X1441, JX14P, JX14P-RT, JX39P, JX39P-RT and normal human astrocytes (NHA) as control and screened for viability with Cell Titer-Glo. We identified multiple candidate drugs that preferentially killed GBM PDX cells at 10 µM relative to NHA control. As we used stem cell media (serum free) in our drug screening study, it indicates that the potent drugs are also effective in killing cancer stem cells or brain tumor initiating cells. These drugs had targets ranging from PDGFR, DNA/RNA synthesis, as well as other kinase inhibitors. We developed a high throughput (HT), neurosphere based colony formation assay (CFA) in 96-well plate to screen multiple drugs and doses in combination with radiation. For visualizing the colonies, we use a Cytation 5 imager at 4X resolution and count the colonies based on parameters including object size, width, intensity and others. We plan on validating our drug screen and HT-CFA assay with high throughput PamChip kinase activity assays and with in vivo orthotopic tumor PDX models.
CCRG-01. MYT1 BLOCKADE AS A NOVEL GLIOMA THERAPEUTICS THROUGH ABROGATIING OF THE G2/M CELL CYCLE CHECKPOINT
Authors: Lang Fengchao , Cornwell James , Zhang Wei , Zhang Meili , Song Hua , Aladjem Mirit , Aregger Michael , Cappell Steven , Yang Chunzhang 
Published: November 2024

Abstract

BACKGROUND
The cell cycle is tightly regulated by checkpoints, which play a vital role in controlling its progression and timing. Cancer cells exploit the G2/M checkpoint, which serves as a resistance mechanism against genotoxic anticancer treatments, allowing for DNA repair prior to cell division. Manipulating cell cycle timing has emerged as a potential strategy to augment the effectiveness of DNA damage-based therapies.

METHODS
In this study, we conducted a forward genome-wide CRISPR/Cas9 screening with repeated exposure to the alkylating agent temozolomide (TMZ) to investigate the mechanisms underlying tumor cell survival under genotoxic stress. The screening hits were validated through in patient derived glioma cells and xenografts.

RESULTS
Our findings revealed that canonical DNA repair pathways, including the Ataxia–telangiectasia mutated (ATM)/Fanconi and mismatch repair, determine cell fate under genotoxic stress. Notably, we identified the critical role of PKMYT1, in ensuring cell survival. Depletion of PKMYT1 led to overwhelming TMZ-induced cytotoxicity in cancer cells. Isobologram analysis demonstrated potent drug synergy between alkylating agents and a Myt1 kinase inhibitor, RP-6306. Mechanistically, inhibiting Myt1 forced G2/M-arrested cells into an unscheduled transition to the mitotic phase without complete resolution of DNA damage. This forced entry into mitosis, along with persistent DNA damage, resulted in severe mitotic abnormalities. Ultimately, these aberrations led to mitotic exit with substantial apoptosis. Preclinical animal studies demonstrated that the combination regimen involving TMZ and RP-6306 prolonged the overall survival of glioma-bearing mice.
CSIG-01. DECREASING EXPRESSION OF TRAF PROTEINS WITH INCREASING MALIGNANCY WITH LOWEST EXPRESSION IN IDH-WILDTYP GLIOBLASTOMA
Authors: Timmer Marco , Kuhl Saskia , Goldbrunner Roland 
Published: November 2024

Abstract
The tumor necrosis factor receptor-associated factors (TRAF) are cytoplasmatic adapter proteins that can interact directly with the intracellular domains of cell surface receptors, such as the TNF receptor superfamily. TRAFs are thus involved in cellular processes like proliferation or apoptosis. Seven members are known; all expressed in the cytosol of various cell and tissue types. Increased levels of TRAF4 in GBM tissue are related to cell proliferation and migration. About 25 % of grade I meningioma show mutations in TRAF7, which are associated with a lower risk of malignant transformation. Therefore expression patterns of all seven TRAF members are evaluated in different glioma grades. Following tumor samples were obtained during neurosurgery and shock frozen in liquid nitrogen: peritumoral tissue, astrocytoma and oligodendroglioma (G2, G3) and glioblastoma (primary and recurrent). Transcription rate of TRAF1-7 was measured via qPCR. Correlation of TRAF expression level and patient overall survival was evaluated using TCGA datasets of the TCGA-LGG” and “TCGA-GBM” projects. With the exception of TRAF5, a decreased mRNA level with increasing malignancy could be found for all TRAFs (TRAF1 p=n.s.; TRAF2 p=0.0026; TRAF3 p&lt;0.0001; TRAF4 p=0.0021; TRAF6 p&lt;0.0001; TRAF7 p&lt;0.0001). IDHwt glioblastoma showed significant lower expression level compared to IDHmut glioblstoma in all TRAFs except for TRAF1 (TRAF2 p&lt;0.0001; TRAF3 p=0.0346; TRAF4 p&lt;0.0001; TRAF6 p=0.0447; TRAF7 p=0.0081). TRAF5 again showed a reverse effect (p=0.0065). Correlation of TRAF expression level in low grade glioma and patient survival revealed longer overall survival with low TRAF1,2,4 and TRAF5 expression (p&lt;0.0001, p= 0.0178, p=0.0307, p&lt;0.0001). No difference in survival rate in high grade glioma could be found.
CSIG-03. MT-125 INHIBITS NON-MUSCLE MYOSIN IIA AND IIB, SYNERGIZES WITH ONCOGENIC KINASE INHIBITORS, AND PROLONGS SURVIVAL IN GLIOBLASTOMA
Authors: Rosenfeld Steven , kenchappa rajappa , Radnai Laszlo , Zarco Natanael , Dovas Athanassios , Haddock Ashley , Canoll Peter , Rumbaugh Gavin , Griffin Patrick , Kamenecka Theodore , Miller Courtney 
Published: November 2024

Abstract
We have shown that members of the non-muscle myosin II (NMII) family of molecular motors are non-redundant drivers of both invasion and proliferation in glioblastoma (GBM), consistent with the canonical roles NMII isoforms play in cell motility and cytokinesis. However, we have also found that NMII also has a non-canonical role by regulating oncogenic signaling pathways relevant to GBM pathogenesis. This unexpected finding has led us to identify and characterize MT-125, a highly specific small molecule inhibitor of the two predominant NMII isoforms in GBM (NMIIA and NMIIB), and we have studied its effects in pre-clinical GBM models. MT-125 has high brain penetrance and retention; an excellent safety profile in rodents and canines with no changes in metabolic or hematologic indices after prolonged administration; is well-tolerated with daily dosing for at least 85 consecutive days; blocks GBM invasion and cytokinesis, consistent with the canonical roles of NMII; and prolongs median survival by 35% as a single agent in murine GBM models. MT-125 increases signaling along both the PDGFR- and MAPK-driven pathways through a mechanism that involves the upregulation of reactive oxygen species, leading to oncogene addiction to these pathways. As a consequence, MT-125 is synthetically lethal when combined with FDA-approved, CNS-permeant inhibitors of PDGFR and mTOR in vitro. Combining MT-125 with sunitinib, a PDGFR inhibitor, or paxalisib, a combined PI3 Kinase/mTOR inhibitor, in vivo doubles median survival in a highly aggressive murine orthotopic GBM model. Furthermore, combining MT-125 with sunitinib produces tumor free remissions of &gt;100 days--2.5-fold greater than median survival of either drug alone—in approximately 40% of mice. Our results provide a powerful rationale for developing NMII targeting strategies to treat cancer and demonstrate that MT-125 has strong clinical potential for the treatment of GBM.